191 related articles for article (PubMed ID: 33936598)
1. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
3. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
[TBL] [Abstract][Full Text] [Related]
4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
[TBL] [Abstract][Full Text] [Related]
6. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
7. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
8. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
Siddiqi T; Thomas SH; Chen R
Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256
[TBL] [Abstract][Full Text] [Related]
9. How I manage patients with grey zone lymphoma.
Kritharis A; Pilichowska M; Evens AM
Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
Makita S; Maruyama D; Tobinai K
Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
[TBL] [Abstract][Full Text] [Related]
16. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
17. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
18. Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant.
Goto A; Fujita C; Horiguchi H; Iyama S; Kobune M
Cureus; 2024 Mar; 16(3):e57291. PubMed ID: 38690456
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin treatment for primary refractory hodgkin lymphoma.
Wu HB; Yeh SA; Chen HY
Case Rep Hematol; 2013; 2013():351292. PubMed ID: 24198983
[TBL] [Abstract][Full Text] [Related]
20. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
